There is a pressing need for novel and more efficient therapies that can target the MET signaling pathway, but for this to be possible, the understanding of how abundant certain genetic alterations are, and how they affect and drive lung cancer development, needs to be further deepened. This evidence concerns the gene MET and lung carcinoma.